Medtronic today announced that it received National Medical Products Administration approval in China for its CoreValve Evolut Pro TAVR system.
The approval marks the first Medtronic TAVR system approved in China for patients with symptomatic severe aortic stenosis who are at high or extreme risk for open-heart surgery, according to the company.